Research programme: vaccine therapeutics - DBV Technologies
Latest Information Update: 23 Apr 2023
At a glance
- Originator DBV Technologies
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 15 Mar 2023 Preclinical trials in Unspecified indication in France (Unspecified) (DBV Technologies pipeline, March 2023)